UK markets open in 2 hours 14 minutes

Biotest Aktiengesellschaft (0N70.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
26.10-0.20 (-0.76%)
At close: 3:05PM GMT
Full screen
Previous close26.30
Open26.00
Bid0.00 x 0
Ask0.00 x 0
Day's range26.00 - 26.10
52-week range26.00 - 26.10
Volume8
Avg. volumeN/A
Market cap1.078B
Beta (5Y monthly)0.98
PE ratio (TTM)N/A
EPS (TTM)-0.80
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Biotest AG: Biotests Pentaglobin(R) is a treatment option for COVID-19 patients additionally affected by bacterial infections

    DGAP-News: Biotest AG / Key word(s): Research Update26.11.2020 / 07:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotests Pentaglobin(R) is a treatment option for COVID-19 patients additionally affected by bacterial infections- Secondary bacterial infections increasingly observed when the clinical progression of COVID-19 is severe- Pentaglobin(R) supports the immune system in eliminating bacteria and toxins - Pentaglobin(R) regulates excessive immune responses- Aiming for alleviating of overcrowded intensive care units Dreieich, 26 November 2020. Pentaglobin(R) is the only immunoglobulin M (IgM)-enriched preparation on the global market. It is approved for the treatment of severe bacterial infections with concomitant use of antibiotics. Secondary bacterial infections are increasingly being observed in COVID-19 patients when the clinical progression of the disease is severe. The antibodies in Pentaglobin(R) can bind to many different bacteria and their toxins, assisting in their destruction by the immune system. Also, the IgM content in Pentaglobin(R) supports the immune system and is able to restore the balance of the immune response which is often excessive in COVID-19 patients.With Pentaglobin(R) Biotest is offering an established treatment option for bacterial infections which can also be used to treat severely ill COVID-19 patients. Pentaglobin(R) was able to significantly reduce mortality in patients with sepsis and shorten the length of mechanical ventilation.[1] It is therefore conceivable that treatment with Pentaglobin(R) may also reduce the length of and need for mechanical ventilation in COVID-19 patients. This could result in a reduction in the length of stay in intensive care units and ease the strain on limited capacity. First case reports on the use of Pentaglobin(R) in COVID-19 patients show promising results.In addition to this, with trimodulin Biotest is developing a polyvalent antibody preparation to combat COVID-19, as well as a COVID-19 hyper immunoglobulin as part of a plasma alliance cooperation. Biotest is therefore pursuing a number of promising approaches aimed at providing critically ill COVID-19 patients with further effective treatment options as quickly as possible by means of accelerated approval procedures.About Pentaglobin(R)Pentaglobin(R) is the first and only IgM-enriched immunoglobulin preparation for intravenous use. Pentaglobin(R) significantly increases the survival rate of patients with severe bacterial infections and acts against a broad spectrum of bacterial pathogens. Pentaglobin's(R) acts anti-bacterial by fast neutralization of bacterial endo- and exotoxins and anti-inflammatory by scavenging excessively activated complement factors. Pentaglobin(R) is licensed in several countries for the treatment of severe bacterial infections in combination with antibiotics.About COVID-19COVID-19 is a respiratory disease caused by the novel severe acute respiratory syndrome corona virus 2 variant (SARS-CoV-2). While most cases are mild or asymptomatic, COVID-19 patients may present at the hospital with typical signs of pneumonia requiring oxygen support. This disease stage is regularly accompanied by an excessive immune response and can lead to systemic inflammation reactions. Furthermore, patients may progress to critical disease with need for intensive care, including invasive mechanical ventilation. This clinical picture and course of the disease resembles that of severe community acquired pneumonia (sCAP) caused by other pathogens.About BiotestBiotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.IR contactDr Monika ButtkereitPhone: +49-6103-801-4406Mail: investor_relations@biotest.dePR contactDirk NeumüllerPhone: +49-6103-801-269Mail: pr@biotest.comBiotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.comOrdinary shares: securities' ID No. 522720; ISIN DE0005227201Preference shares: securities' ID No. 522723; ISIN DE0005227235Listing: Frankfurt (Prime Standard)Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, TradegateDisclaimerThis document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.[1] Cui et al., Ann. Intensive Care 2019, 9 (1):27. doi: 10.1186/s13613-019-0501-3.26.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1150631   End of News DGAP News Service

  • EQS Group

    Biotest AG: Biotest increases adjusted 9-month EBIT by over 21% to € 52 million

    DGAP-News: Biotest AG / Key word(s): Quarter Results12.11.2020 / 07:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest increases adjusted 9-month EBIT by over 21% to € 52 million - Sales increase by over 15% to € 324 million- Two development projects for COVID-19 therapy further advanced- Guidance for 2020 confirmedDreieich, November 12, 2020. In the first nine months of the 2020 financial year, the Biotest Group recorded adjusted EBIT of € 51.6 million. Compared to € 42.6 million in the same period of the previous year, this represents an increase of 21.1 %. The adjusted EBIT does not include the costs for the Biotest Next Level expansion project in the amount of € 59.3 million (same period of the previous year: € 49.7 million). The adjusted EBIT margin rose to 15.1 % in the first nine months of the current fiscal year, compared to 14.4 % in the same period last year.At € 341.6 million (same period in the previous year: € 294.9 million), revenues for the first nine months of 2020 were also significantly up by € 46.7 million or 15.8 % versus the same period in the previous year. The strong increase is attributable to the Therapy and Plasma & Services segments. The 14.1 %(€ 37.6 million) increase in the Therapy segment resulted both from increased sales volumes and from higher sales prices of important products such as Intratect(R) and human albumin. Sales growth in the Plasma & Services segment of 43.8 % (€ 10.3 million) was driven by a pleasing increase in contract fractionation.EBIT improved slightly by € 0.4 million compared to the same period of the previous year and amounted to € -7.8 million (prior year period: € -8.2 million) for the first nine months of the 2020 financial year.Both development projects for the therapy of COVID-19 infections made good progress:Due to the great similarity of the clinical picture to the patients treated in the CIGMA study, Biotest sees Trimodulin as having considerable potential for patients with severe pneumonia after a COVID-19 infection. A phase II study (ESsCOVID - Escape from severe COVID-19) with COVID-19 patients was approved in order to accelerate the development of Trimodulin in view of the current COVID-19 pandemic. Plans for accelerated development have been discussed with the regulatory authorities in Europe and the USA. The study design was submitted to the competent authority and the Ethics Committee in Spain, Brazil, Russia and France. The study design has already been approved in Spain, Russia and Brazil. In parallel, Biotest is expanding its planned phase III study in sCAP to include COVID-19 patients.Biotest is also working on a new drug against COVID-19 based on plasma donations from donors previously recovered from COVID-19. The donations contain antibodies that can neutralize the coronavirus. This drug contains these antibodies in a purified form and could then be used therapeutically against COVID-19. In order to advance the development as quickly as possible, Biotest has entered into an industry-wide cooperation within the COVID-19 Plasma Alliance with companies such as CSL, LFB, Octapharma and Takeda. This alliance is developing this polyclonal hyperimmunoglobulin treatment for SARS-CoV-2.In order to expand the product range and double production capacity, Biotest started the expansion project Biotest Next Level. In financial year 2020, further progress was made with this project. In June the second approval took place and in October 2020, another partial inspection for the commissioning of the BNL plant took place by the Darmstadt Regional Council. The main focus of the inspection was the new SAP-based software for the collection and management of the raw material plasma and plasma based intermediate products.Despite some difficulties caused by the Corona pandemic, the commissioning of the BNL production plant is progressing. In the second quarter of 2021, the manufacturing license in according to §13 of the German Medicines Act (AMG) is to be obtained.Outlook:The Board of Management expects sales growth of around 10 % for financial year 2020. Earnings in 2020 will be influenced by various factors. Besides the expected expenses of € 80 million to € 90 million from the Biotest Next Level expansion project, including the associated research and development costs, the tense situation in the crisis regions, particularly in the Middle East and Asia, could also have an impact. Based on the aforementioned factors, the Board of Management expects EBIT to be between € -10 million and € -5 million. In particular as consequence of the increased expenditures on the two new COVID-19 studies the Management Board expects that earnings will be at the lower end of the range given.The nine month report is available on the company's website https://www.biotest.com/de/en/investor_relations/news_and_publications/publications/quarterly_reports.cfmAbout BiotestBiotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.IR contactDr Monika ButtkereitPhone: +49-6103-801-4406Mail: investor_relations@biotest.dePR contactDirk NeumüllerPhone: +49-6103-801-269Mail: pr@biotest.comBiotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.comOrdinary shares: securities' ID No. 522720; ISIN DE0005227201Preference shares: securities' ID No. 522723; ISIN DE0005227235Listing: Frankfurt (Prime Standard)Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, TradegateDisclaimerThis document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.12.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1147438   End of News DGAP News Service

  • EQS Group

    Biotest AG: Biotest treats first COVID-19 patient with trimodulin

    DGAP-News: Biotest AG / Key word(s): Research Update06.10.2020 / 12:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest treats first COVID-19 patient with trimodulin- A clear reduction in mortality and in duration of ventilation support during intensive care stay is expected- Worldwide unique, innovative plasma protein preparation for treatment of COVID-19 patients- Expedited approval of trimodulin for COVID-19 intended Dreieich, 6 October 2020. Biotest announced today that the first patient with severe COVID-19 was treated in Spain with trimodulin in the ESsCOVID (Escape from severe COVID-19) trial. Furthermore has the trial been submitted for approval to the Regulatory Agencies in Russia, Brazil and now also in France.In this multinational phase II clinical trial, approximately 160 adult patients with severe COVID-19 are planned to be enrolled. These are patients with pneumonia or acute respiratory distress syndrome (ARDS) admitted to hospital due to the severity of their disease. After confirmation of SARS-CoV-2 infection and presence of a strong inflammatory response, the patients will be treated either with trimodulin or with placebo as add-on therapy to standard of care.The clinical concept of this prospective, double-blind, placebo-controlled phase II trial, was developed according to the expectations of the European Medicines Agency (EMA) after a so-called "Rapid Scientific Advice". Biotest aims for an expedited approval of trimodulin to rapidly respond to the need for novel treatment options for patients with severe COVID-19.Biotest's development product trimodulin is a worldwide unique, innovative antibody preparation. Trimodulin treatment has already demonstrated promising results in a phase II clinical trial with 160 invasive mechanically ventilated patients suffering from severe community-acquired pneumonia (sCAP) with a strong inflammatory response (CIGMA trial).The similarity of the COVID-19 symptoms to the patients treated in the CIGMA trial, justifies the hypothesis that trimodulin has a considerable potential in the treatment of SARS-CoV-2 induced pneumonia."We are very pleased, to be able to support physicians with trimodulin for the treatment of patients with severe COVID-19. We hope, that trimodulin will be able to prevent progression of disease and improve patient outcome. As this would also reduce to need for invasive mechanical ventilation, it could alleviate possible capacity limitations within intensive care units", said Daniela Zipp, responsible Head of Clinical Operations at Biotest.About COVID-19COVID-19 is a respiratory disease caused by the novel severe acute respiratory syndrome corona virus 2 variant (SARS-CoV-2). While most cases are mild or asymptomatic, COVID-19 patients may present at the hospital with typical signs of pneumonia requiring oxygen support. This disease stage is regularly accompanied by an excessive immune response and can lead to systemic inflammation reactions. Furthermore, patients may progress to critical disease with need for intensive care, including invasive mechanical ventilation. This clinical picture and course of the disease resembles that of sCAP caused by other pathogens.About trimodulin (IgM Concentrate)Biotest' development product trimodulin is an innovative immunoglobulin preparation, purified from human blood plasma. In comparison to standard IgG preparations (IVIG), trimodulin contains relevant amounts of IgM and IgA in addition to IgG. Trimodulin is currently in clinical development for the treatment of patients with severe community-acquired pneumonia (sCAP) and for patients with severe COVID-19. Research so far has shown that trimodulin could interfere with a number of mechanisms involved in pathological processes that would otherwise lead to respiratory failure, sepsis, multi-organ failure and finally to death of the patient. Due to the large variety of polyvalent antibodies present in trimodulin, the impaired immune system is supported in various ways. The antibodies bind to various types of pathogens including viruses and bacteria as well as their toxins and support their clearance by the immune system. Particularly the IgM component in trimodulin can reduce dysregulated immune responses, preventing the immune system to attack host tissues, in this case, the lung. In this way, trimodulin may prevent progression of disease, including the need for invasive mechanical ventilation and other intensive care procedures.About BiotestBiotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.IR contactDr Monika ButtkereitPhone: +49-6103-801-4406Mail: investor_relations@biotest.dePR contactDirk NeumüllerPhone: +49-6103-801-269Mail: pr@biotest.comBiotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.comOrdinary shares: securities' ID No. 522720; ISIN DE0005227201Preference shares: securities' ID No. 522723; ISIN DE0005227235Listing: Frankfurt (Prime Standard)Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, TradegateDisclaimerThis document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.06.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1139155   End of News DGAP News Service